

April 15, 2009

Syntagon to supply clinical material for Parkinson's, Huntington's research

Specialist contract research organisation, Syntagon AB, is to develop the lead compound for Phase I clinical trials carried out by A. Carlsson Research AB into Parkinson's disease, Huntington's disease and Brain Fatigue.

"We are immensely proud to be a part of this new phase of research into these three debilitating conditions," says John Cameron, Syntagon Director of Sales & Marketing Europe.

In the first set of clinical trials, A. Carlsson Research will explore the effect of OSU 6162 on Parkinson's, Huntington's and Brain Fatigue.

Arvid Carlsson, CEO of Arvid Carlsson Research, won the Nobel Prize in Physiology or Medicine in 2000 for his discovery of dopamine's function as a neurotransmitter. His research resulted in the discovery that Parkinson's is caused by a lack of dopamine in certain parts of the brain.

"We had heard good reports about Syntagon within the Swedish community. They are technically excellent, fast-responding and an ideal partner for a company of our size," Carlsson says.

With twin operations in Södertälje, Sweden, and Riga, Latvia, Syntagon specialises in synthetic preparation of small molecules under GMP manufacture.

Syntagon's extensive pharmaceutical experience, expertise in GMP manufacture, analytical chemistry and crystallisation are tailored for all client types: from single-product start-ups, to global pharmaceutical groups.

Syntagon is a leading Scandinavia-based drug development partner. We develop compounds from lead optimisation to phase II clinical trials using the latest technology and equipment combined with a solid quality system.

For further details on this press release, please contact John Cameron, Syntagon Director of Sales & Marketing Europe at john.cameron@syntagon.se.